First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
Conclusion:
AnP is not a cost-effective choice as the first-line treatment for advanced triple-negative breast cancer in the United States and China.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Breast Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | China Health | Clinical Trials | Health Management | Study | USA Health